Full Coverage

Covidien Announces Agreement with Purdue Pharma L.P. Enabling Launch of Oxycodone Hydrochloride...

                   
pharmiweb.co.uk
02-Sep-2008
        
Story Timeline:  91 days

MANSFIELD, Mass. -- (Business Wire) Covidien (NYSE: COV, BSX: COV), a leading global provider of healthcare products, today announced that its subsidiary, Mallinckrodt Inc., has reached an agreement with Purdue Pharma L.P. to end a patent infringement lawsuit between them. In connection with the agreement, Purdue has agreed to grant Mallinckrodt a royalty-bearing license to sell limited quantities of oxycodone... [read full story]                    

Add Comment
Latest article on this story:

Covidien (COV) NewsBite - Covidien Signs Agreement with Purdue Pharma

 pharmiweb.co.uk 02-Sep-2008
First article on this story:

Purdue Pharma L.P. Announces Resolution of OxyContin(R) Patent Lawsuit with Mallinckrodt Inc

 pharmiweb.co.uk 02-Sep-2008
Selected publications with coverage of this story:
ibtimes.com drugpolicycentral.com pharmiweb.co.uk
RELATED
Found 3 documents:

Covidien (COV) NewsBite - Covidien Signs Agreement with Purdue Pharma

pharmiweb.co.uk
02-Sep-2008
        

Posted on Tuesday, September 02, 2008 1:53 PM Covidien (NYSE: COV) hit a new 52-Week high of $55.15 so far today. Currently the stock is up $0.72 (1.33%) to $54.79 on 2,647,188 shares traded. Today's high is up $17.06...

                   

Covidien Announces Agreement with Purdue Pharma L.P. Enabling

pharmiweb.co.uk
02-Sep-2008
        

Stocks mentioned in this article , a leading global provider of healthcare products, today announced that its subsidiary, Mallinckrodt Inc., has reached an agreement with Purdue Pharma L.P. to end a patent infringement...

                   

Purdue Pharma L.P. Announces Resolution of OxyContin(R) Patent Lawsuit with Mallinckrodt Inc

pharmiweb.co.uk
02-Sep-2008
        

Mallinckrodt acknowledges validity of Purdue patents; Purdue licenses limited sales of some generic oxycodone strengths STAMFORD, Conn., Sept. 2 /PRNewswire/ -- Purdue Pharma L.P. of Stamford, Connecticut and Mallinckrodt...